novartis india investor presentation

• Super Investors
•  Account
• Share Holding
• Balance Sheet
• Corp. Action

Novartis share price

NSE:  NOVARTIND BSE:  500672 SECTOR:  Trading   21k    39    4

Price Summary

₹  1064

₹  1055

₹  1224

₹  599.95

Ownership Stable

Valuation fair, efficiency poor, financials very stable, company essentials.

₹ 2617.22 Cr.

₹ 2061.28 Cr.

₹  301.66

₹ 555.94 Cr.

₹ 0 Cr.

₹  34.5

Add Your Ratio

Your Added Ratios

Index presence.

The company is present in 4 Indices.

S&P MIDSMLCAP

• Price Chart
• Volume Chart

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

Volume chart 1d 1w 1m 3m 6m 1yr 3yr 5yr, pe chart 1w 1m 3m 6m 1yr 3yr 5yr, pb chart 1w 1m 3m 6m 1yr 3yr 5yr, peer comparison,  group companies.

Track the companies of Group.

Sales Growth

Profit growth, debt/equity, price to cash flow, interest cover ratio, cfo/pat (5 yr. avg.).

Share Holding Pattern

Promoter pledging %,  strengths.

• The company has shown a good profit growth of 117.252103201553 % for the Past 3 years.
• Company is virtually debt free.
• Company has a healthy Interest coverage ratio of 66.9314285714286 .
• Company’s PEG ratio is 0.0106730576854162 .
• The company has an efficient Cash Conversion Cycle of -42.9235928261754 days.
• Company has a healthy liquidity position with current ratio of 2.93021695370163 .
• The company has a high promoter holding of 70.68 %.

 Limitations

• The company has shown a poor revenue growth of -4.74817736197044 % for the Past 3 years.
• Company has a poor ROE of 5.48144208459798 % over the past 3 years.
• Company has contingent liabilities of 419.25 Cr.
• Tax rate is low at 10.4177500433351 .

Quarterly Result (All Figures in Cr.)

Profit & loss (all figures in cr. adjusted eps in rs.), balance sheet (all figures are in crores.), cash flows (all figures are in crores.), corporate actions dividend bonus rights split, investors details promoter investors, annual reports.

• Annual Report 2022 1 Jul 2022
• Annual Report 2021 4 Aug 2021
• Annual Report 2020 11 Jul 2020
• Annual Report 2019 9 Jan 2020
• Annual Report 2018 9 Jan 2020
• Annual Report 2017 2 Apr 2021

Ratings & Research Reports

Company presentations.

Company News

Novartis stock price analysis and quick research report. is novartis an attractive stock to invest in.

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Novartis stock price today is  Rs 672.25 . Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Novartis . 

PE ratio : Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Novartis has a PE ratio of 19.4839824129706  which is high and comparatively overvalued .

Share Price : - The current share price of Novartis is Rs 672.25 . One can use valuation calculators of ticker to know if Novartis share price is undervalued or overvalued.

Return on Assets (ROA) : - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Novartis has ROA of 5.08929406724998 % which is a bad sign for future performance. (higher values are always desirable)

Current ratio : - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Novartis has a Current ratio of 2.93021695370163 .

Return on equity : - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Novartis has a ROE of 14.0662212000381 % .(higher is better)

Debt to equity ratio : - It is a good metric to check out the capital structure along with its performance. Novartis has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

Sales growth : - Novartis has reported revenue growth of - 5.28421737064545 % which is poor in relation to its growth and performance. 

Operating Margin : - This will tell you about the operational efficiency of the company. The operating margin of Novartis for the current financial year is 17.1832919681048 % .

Dividend Yield : - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Novartis is Rs 47.5  and the yield is 2.3637   % .

Earnings Per Share : - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Novartis is Rs 34.5027 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Novartis in Ticker for free. Also, one can get the intrinsic value of Novartis by using Valuation Calculators, which are available with a Finology ONE subscription. 

Brief about Novartis

Novartis india ltd. financials: check share price, balance sheet, annual report, quarterly results, shareholding, company profile and news for company analysis.

Novartis India Ltd. is a leading pharmaceutical company in India. It is a subsidiary of the global healthcare company Novartis AG. Novartis India has been operating in the country for several decades and has established itself as a trusted provider of high-quality medicines.

Novartis India Ltd. - Share Price

Stay updated with the latest share price of Novartis India Ltd. Our website provides real-time stock prices along with historical data. Our pre-built screening tools allow you to analyze the share price performance of Novartis India over different time periods.

Novartis India Ltd. - Balance Sheet

Access the balance sheet of Novartis India Ltd. on our website. Our premium features enable fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools help long-term stock investors gain insights into the financial health of the company.

Novartis India Ltd. - Annual Report

Download the annual reports of Novartis India Ltd. from our website. The annual reports provide a comprehensive overview of the company's performance, financials, and strategic initiatives. They are valuable resources for investors to assess the company's long-term prospects.

Novartis India Ltd. - Dividend

Track the dividend history of Novartis India Ltd. on our website. Dividends are an important consideration for many investors looking for stable income from their investments. Novartis India regularly evaluates and announces dividends to reward its shareholders.

Novartis India Ltd. - Quarterly Results

Stay informed about the quarterly results of Novartis India Ltd. Our website provides access to the latest financial reports and insights from earnings calls. These reports help investors track the company's performance and make informed investment decisions.

Novartis India Ltd. - Stock Price

Analyze the stock price movement of Novartis India Ltd. on our website. Our pre-built screening tools and price charts allow investors to track the stock's historical performance and identify potential investment opportunities.

Novartis India Ltd. - Price Chart

Visualize the price chart of Novartis India Ltd. on our website. Price charts provide a graphical representation of the stock's price movement over time, helping investors spot trends, patterns, and potential support and resistance levels.

Novartis India Ltd. - News

Access the latest news updates about Novartis India Ltd. Our website provides a curated feed of news articles and press releases related to the company. Stay informed about the latest developments that may impact your investment decisions.

Novartis India Ltd. - Concall Transcripts

Download the concall transcripts of Novartis India Ltd. from our website. Concall transcripts are valuable resources that provide insights into the company's performance, management commentary, and future outlook as discussed during the earnings calls.

Novartis India Ltd. - Investor Presentations

Find investor presentations of Novartis India Ltd. on our website. Investor presentations offer a comprehensive overview of the company's strategy, financials, and operational highlights. These presentations are useful for investors to understand the company's business and investment potential.

Novartis India Ltd. - Promoters

Learn about the promoters of Novartis India Ltd. Promoters play a crucial role in the company's management and decision-making process. Our website provides information about the promoters and their contribution to the company's growth.

Novartis India Ltd. - Shareholders

Explore information about the shareholders of Novartis India Ltd. Shareholders play a significant role in the company's ownership and governance. Our website provides insights into the major shareholders of Novartis India and their stake in the company.

By providing comprehensive stock analysis tools, access to key financial reports, and curated news updates, our website aims to empower long-term stock investors in making informed decisions regarding Novartis India Ltd. Stay updated with the latest information and leverage our premium features for fair value calculations and in-depth analysis.

Ratio Delete Confirmation

Novartis India Ltd

Performance

Hasn't fared well - amongst the low performers

Seems to be overvalued vs the market average

Lagging behind the market in financials growth

Profitability

Showing good signs of profitability & efficiency

Entry point

The stock is overpriced but is not in the overbought zone

No red flag found

Go Pro! to unlock score, rank

and other metrics

How to use scorecard? Learn more

Financial Statements

Balance Sheet

What is an income statement?

The income statement indicates a company's financial performance measured over a reporting period. Performance is assessed by summarising how the business incurs its revenues, expenses and net profit or loss incurred over the period. It's also called the P&L statement

Income Statement

Lower than industry revenue growth a higher-than-industry revenue growth represents increased potential for the company to increase their market share.

Over the last 5 years, revenue has grown at a yearly rate of -9.9%, vs industry avg of 8.34%

Decreasing Market Share Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.36% to 0.13%

Lower than Industry Net Income Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 5.69%, vs industry avg of 9.77%

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual report

• NOVARTIS INDIA LTD.
• SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
• INDUSTRY : PHARMACEUTICALS

Novartis India Ltd.

BSE: 500672

/100 Valuation Score : 33 /100 Momentum Score : 62 /100 "> Strong Performer, Getting Expensive

1055.00 -2.65 ( -0.25 %)

75.85% Gain from 52W Low

33,428 BSE Volume

BSE 04 Jun, 2024 11:11 AM (IST)

• Share on Facebook
• Share on LinkedIn
• Share via Whatsapp

Operating Revenue TTM

Below industry Median

Net profit TTM

Net Profit Margin TTM %

Revenue Growth (TTM)

Negative Operating Revenue growth TTM %

Net Profit TTM Growth %

Negative Net Profit TTM Growth %

Novartis India Ltd. Credit Ratings

IOWA Research Park

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present information pertaining to the Company's sponsored studies of its assets at the Society of Nuclear Medicine & Molecular Imaging ("SNMMI") Annual Meeting 2024, which is being held in Toronto, Canada, from June 8-11, 2024. The Company notes that results based on investigator-initiated use of its assets are also being presented.  

"We are greatly encouraged by the progress of our clinical and preclinical programs," said Thijs Spoor, CEO of Perspective. "The upcoming presentations at the SNMMI meeting will showcase our activities with VMT-α-NET and other promising therapies, underlining our commitment to advancing care for patients battling challenging tumor types."

[ 212 Pb]VMT-α-NET for the Treatment of Neuroendocrine Tumors The abstract describing Perspective's trial in progress of the Phase 1/2a dose escalation study (NCT05636618) in patients with unresectable or metastatic somatostatin receptor type 2 ("SSTR2")-positive neuroendocrine tumors ("NETs") who have not received prior peptide receptor radionuclide therapies ("PRRT") stated the trial's status as of January 15, 2024, consistent with the abstract submission deadline for the SNMMI conference. Updates on this trial as of March 7, 2024 were provided during the Company's investor update on March 18, 2024, accessible on the events page of the Company's website. This study, in conjunction with the Phase 0 imaging study (NCT05111509), would inform the recommended Phase 2 dose of [ 212 Pb]VMT-α-NET.

Perspective, in collaborating independent investigators, is evaluating dosimetry and the applicability of patient-specific dosing as determined by a target renal absorbed dose for [ 212 Pb]VMT-α-NET. An abstract reported pooled data from ten patients recruited in the Company's sponsored Phase 0 imaging study and an investigator sponsored absorbed dose escalation study. The investigator reported [ 212 Pb]VMT-α-NET was prescribed to three patients at individualized doses of 5.3, 7.9, and 13.3 mCi (cumulatively, delivered over two cycles) while targeting renal absorbed dose of 3.5Gy. Higher levels of targeted renal absorbed doses are in the protocol for subsequent cohorts of the investigator sponsored study.

The Company has been informed that updated results from the investigator initiated trial of [ 212 Pb]VMT-α-NET in India have been accepted for presentation by the SNMMI conference. The investigator enrolled adult patients with histologically confirmed NETs and metastatic medullary thyroid carcinomas. The investigator informed the Company that the update includes results from 12 patients at a later data cutoff date than previous presentations. The most recent prior public update by the investigator was during the 36 th Annual Congress of the European Association of Nuclear Medicine (EANM) in September 2023.

Preclinical Progress on Targeted Therapies for Melanoma and Tumor Environments

The Company will present preclinical data for [ 212 Pb]VMT01, a targeted α-particle radionuclide therapy (α-TRT) targeting the melanocortin 1 receptor ("MC1R"), used in combination with immune checkpoint inhibitors ("ICIs") in diverse murine melanoma models with high (B16-F10), mid (YUMM-D3) and low (YUMMwt) expressions of MC1R. These data provide a rationale for advancing the combination of [ 212 Pb]VMT01 and ICIs to clinical investigations. The ongoing Phase 1/2a study of [ 212 Pb]VMT01 is being amended to evaluate the safety and tolerability of Perspective's [ 212 Pb]VMT01 in combination with the ICI nivolumab in patients with histologically confirmed melanoma and MC1R-positive imaging scans.

The final presentation will introduce [ 203/212 Pb]-PSV-359, a novel cyclic peptide developed to target fibroblast activation protein alpha ("FAP"), a protein abundantly expressed by cancer-associated fibroblasts in tumor lesions and involved in promoting disease progression. [ 203/212 Pb]-PSV-359 has a proprietary targeting moiety designed by Perspective to optimize "theranostic" applications, representing a promising avenue for addressing FAP expressing cancers regardless of disease site.

About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212 Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com .

Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; the Company's expectation that its clinical and preclinical programs will continue to progress; the Company's belief that it will showcase its activities with VMT-α-Net and other promising therapies at the Society of Nuclear Medicine and Molecular Imaging meeting, underlining the Company's commitment to advancing care for patients battling challenging tumor types; the Company's belief that [ 203/212 Pb]-PSV-359, a novel cyclic peptide, has the ability to target fibroblast activation protein alpha, a protein abundantly expressed by cancer-associated fibroblasts in tumor lesions and involved in promoting disease progression; the Company's belief that it has designed a proprietary targeting moiety for [ 203/212 Pb]PSV359 to optimize "theranostic" applications, representing a promising avenue for addressing FAP expressing cancers regardless of disease site; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting peptides provide the opportunity to personalize treatment and optimize patient outcomes; the Company's expectation that its "theranostic" approach enables the ability to see specific tumors and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to develop a proprietary 212 Pb generator to secure key isotopes for clinical trial and commercial operations; the Company's clinical development plans and the expected timing thereof; the expected timing for availability and release of data; expectations regarding the potential market opportunities for the Company's product candidates; the potential functionality, capabilities, and benefits of the Company's product candidates and the potential application of these product candidates for other disease indications; the Company's expectations, beliefs, intentions, and strategies regarding the future; the Company's intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the potential that regulatory authorities may not grant or may delay approval for the Company's product candidates; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; pre-clinical and early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of regulatory authorities may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company's ability to obtain and maintain regulatory approval for the Company's product candidates; delays, interruptions or failures in the manufacture and supply of the Company's product candidates; the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its clinical development programs; the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of its product candidates; the ability of the Company to manage growth and successfully integrate its businesses; the Company's ability to maintain its key employees; sufficient training and use of the Company's products and product candidates; the market acceptance and recognition of the Company's products and product candidates; the Company's ability to maintain and enforce its intellectual property rights; the Company's ability to maintain its therapeutic isotope supply agreement with the Department of Energy; the Company's ability to continue to comply with the procedures and regulatory requirements mandated by the FDA for additional trials, Phase 1 and 2 approvals, Fast Track approvals, and 510(k) approval and reimbursement codes; and any changes in applicable laws and regulations. Other factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov . Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Perspective Therapeutics IR: Annie Cheng [email protected]

Russo Partners, LLC Nic Johnson / Adanna G. Alexander, Ph.D.

[email protected]